MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Thermo Fisher Scientific Inc

Suletud

SektorTervishoid

482.34 -3.02

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

480.83

Max

497.32

Põhinäitajad

By Trading Economics

Sissetulek

194M

1.8B

Müük

795M

11B

P/E

Sektori keskmine

30.121

73.239

Aktsiakasum

6.1

Dividenditootlus

0.35

Kasumimarginaal

16.007

Töötajad

125,000

EBITDA

377M

3B

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+33.04% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.35%

3.06%

Järgmine tulemuste avaldamine

23. apr 2025

Järgmine dividendimakse kuupäev

15. apr 2025

Järgmine aktsia dividendi kuupäev (ex-date)

13. juuni 2025

Turustatistika

By TradingEconomics

Turukapital

-40B

189B

Eelmine avamishind

485.36

Eelmine sulgemishind

482.34

Uudiste sentiment

By Acuity

29%

71%

78 / 386 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

Thermo Fisher Scientific Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

25. veebr 2025, 14:05 UTC

Omandamised, ülevõtmised, äriostud

Thermo Fisher Scientific to Acquire Solventum's Filtration Unit, Confirming WSJ Report

30. jaan 2025, 11:43 UTC

Tulu

Thermo Fisher Scientific Profit, Revenue Rose in 4Q

23. okt 2024, 10:43 UTC

Tulu

Thermo Fisher Raises Floor of Earnings Target After Steady 3Q Sales

25. veebr 2025, 14:09 UTC

Omandamised, ülevõtmised, äriostud

Thermo Fisher Strikes Deal for Solventum's Filtration Unit -- WSJ

25. veebr 2025, 13:41 UTC

Omandamised, ülevõtmised, äriostud

Solventum: Transaction Is Expected to Be Completed by End of 2025 >SOLV

25. veebr 2025, 13:40 UTC

Omandamised, ülevõtmised, äriostud

Solventum Expects Estimated $3.4 B in Net Proceeds >SOLV

25. veebr 2025, 13:40 UTC

Omandamised, ülevõtmised, äriostud

Solventum: Deal Strengthens Balance Sheet With Proceeds to Be Used Primarily for Debt Paydown >SOLV

25. veebr 2025, 13:40 UTC

Omandamised, ülevõtmised, äriostud

Solventum Expects Deal to Be Neutral to 2025 EPS >SOLV

25. veebr 2025, 13:40 UTC

Omandamised, ülevõtmised, äriostud

Solventum: Deal Accelerates Business Transformation and Sharpens Focus on Strategic Areas for Growth

25. veebr 2025, 13:39 UTC

Omandamised, ülevõtmised, äriostud

Solventum Announces Sale of Its Purification & Filtration Business to Thermo Fisher Scientific Inc. for $4.1B

25. veebr 2025, 13:33 UTC

Omandamised, ülevõtmised, äriostud

Thermo Fisher: Solventum Business Generated About $1 Billion Revenue in 2024 >TMO

25. veebr 2025, 13:32 UTC

Omandamised, ülevõtmised, äriostud

Thermo Fisher to Buy Solventum Purification, Filtration Business for About $4.1 Billion Cash >TMO SOLV

25. veebr 2025, 13:32 UTC

Omandamised, ülevõtmised, äriostud

Thermo Fisher Scientific To Acquire Solventum's Purification And Filtration Business >TMO

24. veebr 2025, 23:03 UTC

Omandamised, ülevõtmised, äriostud

Thermo Fisher Scientific Nears Deal for Solventum's Purification and Filtration Business, Sources Say -- WSJ

24. veebr 2025, 23:03 UTC

Peamised uudised
Omandamised, ülevõtmised, äriostud

Thermo Fisher Nears Deal for Solventum Filtration Unit -- WSJ

24. veebr 2025, 23:03 UTC

Omandamised, ülevõtmised, äriostud

Deal Could be Announced This Week, Sources Say -- WSJ

24. veebr 2025, 23:03 UTC

Omandamised, ülevõtmised, äriostud

Transaction Could Value Solventum Filtration Business Between $3.5B to $4B, Sources Say -- WSJ

30. jaan 2025, 11:06 UTC

Tulu

Thermo Fisher: In a Great Position to Deliver Excellent Performance in 2025 >TMO

30. jaan 2025, 11:05 UTC

Tulu

Thermo Fisher: Will Provide 2025 Fincl Guidance During Earnings Conference Call Thursday Morning >TMO

30. jaan 2025, 11:00 UTC

Tulu

Thermo Fisher 4Q Rev $11.4B >TMO

30. jaan 2025, 11:00 UTC

Tulu

Thermo Fisher 4Q EPS $4.78 >TMO

30. jaan 2025, 11:00 UTC

Tulu

Thermo Fisher 4Q Core Organic Revenue Up 5% >TMO

30. jaan 2025, 11:00 UTC

Tulu

Thermo Fisher 4Q Net $1.83B >TMO

30. jaan 2025, 11:00 UTC

Tulu

Thermo Fisher 4Q Adj EPS $6.10 >TMO

16. dets 2024, 22:03 UTC

Peamised uudised

Novo's New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way. -- Barrons.com

23. okt 2024, 10:02 UTC

Tulu

Thermo Fisher Had Seen 2024 Adjusted EPS $21.29-$22.07 >TMO

23. okt 2024, 10:02 UTC

Tulu

Thermo Fisher Backs 2024 View of Rev $42.4B-$43.3B >TMO

23. okt 2024, 10:00 UTC

Tulu

Thermo Fisher 3Q Core Organic Revenue 0% >TMO

23. okt 2024, 10:00 UTC

Tulu

Thermo Fisher 3Q EPS $4.25 >TMO

23. okt 2024, 10:00 UTC

Tulu

Thermo Fisher 3Q Adj EPS $5.28 >TMO

Võrdlus sarnastega

Hinnamuutus

Thermo Fisher Scientific Inc Prognoos

Hinnasiht

By TipRanks

33.04% tõus

12 kuu keskmine prognoos

Keskmine 662 USD  33.04%

Kõrge 715 USD

Madal 570 USD

Põhineb 18 Wall Streeti analüütiku instrumendi Thermo Fisher Scientific Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

18 ratings

15

Osta

3

Hoia

0

Müü

Tehniline skoor

By Trading Central

N/A / 519.57Toetus ja vastupanu

Lühikene perspektiiv

Strong Bearish Evidence

Keskpikk perspektiiv

Weak Bullish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

78 / 386 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. It has a collaboration agreement with Mainz Biomed N.V. for the development of colorectal cancer screening product. Thermo Fisher Scientific Inc. was founded in 1956 and is headquar